TRV027在急性心衰中的IIb期随机双盲安慰剂对照剂量范围试验
BLAST-AHF是一项多中心、国际、随机、双盲、安慰剂对照、平行组IIb期剂量范围研究,纳入621例急性心衰患者,随机分为安慰剂组或TRV027 1、5、25 mg/h组,静脉输注48-96小时。结果显示TRV027任何剂量均未在主要复合终点或其各组分上优于安慰剂,且无显著安全性问题。
要点
- TRV027任何剂量均未在主要复合终点上优于安慰剂。
- TRV027各剂量对主要复合终点的各组分也均无获益。
- TRV027未出现显著安全性问题。
核心结论
- 在这项IIb期剂量范围急性心衰研究中,TRV027与安慰剂相比未改善至30天随访的临床状态。
研究设计与样本
- 多中心、国际、随机、双盲、安慰剂对照、平行组、IIb期剂量范围研究,纳入621例急性心衰患者,按2:1:2:1分配(中期分析后调整),TRV027 1、5、25 mg/h或安慰剂静脉输注48-96 h,改良意向性治疗分析。
主要发现
- TRV027任何剂量与安慰剂相比,在主要复合终点或任何单个组分上均未带来获益。
- TRV027未出现显著安全性问题。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Currently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the negative effects of angiotensin II, while preserving the potential pro-contractility effects of AT1R stimulation. BLAST-AHF was designed to determine the safety, efficacy, and optimal dose of TRV027 to advance into future studies. METHODS AND RESULTS: BLAST-AHF was a multi-centre, international, randomized, double-blind, placebo-controlled, parallel group, phase IIb dose-ranging study, enrolling patients with AHF into 4 groups: placebo, 1, 5, or 25 mg/h of TRV027. Treatment was by IV infusion for 48-96 h. The primary composite endpoint was comprised of the following: (i) time from baseline to death through day 30, (ii) time from baseline to heart failure re-hospitalization through day 30, (iii) the first assessment time point following worsening heart failure through day 5, (iv) change in dyspnea visual analogue scale (VAS) score calculated as the area under the curve (AUC) representing the change from baseline over time from baseline through day 5, and (v) length of initial hospital stay (in days) from baseline. Analyses were by modified intention-to-treat. Overall, 621 patients were enrolled. After 254 patients, a pre-specified interim analysis resulted in several protocol changes, including a lower blood pressure inclusion criterion as well as a new allocation scheme of 2:1:2:1, overweighting both placebo, and the 5 mg/h dose. TRV027 did not confer any benefit over placebo at any dose with regards to the primary composite endpoint or any of the individual components. There were no significant safety issues with TRV027. CONCLUSION: In this phase IIb dose-ranging AHF study, TRV027 did not improve clinical status through 30-day follow-up compared with placebo.
引用
- Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017. PMID: 28459958. doi:10.1093/eurheartj/ehx196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。